Skip to main content
KBS_Icon_questionmark link-ico
Professor Sandrine Thuret & Dr Edina Silajdzic ;

From researcher to founder: NeuroPrognostix

Professor Sandrine Thuret & Dr Edina Silajdzic

Professor of Neuroscience & Co-founder (Sandrine). Lecturer & Co-founder (Edina)

05 January 2026

Every moment counts when it comes to dementia. Yet, too often, diagnosis comes too late. Professor Sandrine Thuret and Dr Edina Silajdzic are moving beyond scientific questioning and exploring the innovation potential of their research on King’s Spinout Accelerator. They share their experience on the programme and their journey to date.

Which problem is your research seeking to solve? When did you first realise there was commercial potential?

Dementia is usually diagnosed too late. People are missing the window to access new treatments or join clinical trials, which are most effective in the early stages. By the time symptoms show, we’ve often lost valuable time.

Our aim is to shift that timeline: to detect changes in the brain much earlier, ideally before any symptoms appear at all. Our work focuses on a small part of the brain where new brain cells are made throughout life. This process is called ‘neurogenesis’ and it’s important for learning and memory, which starts to break down early in Alzheimer’s disease.

We’ve developed a lab-based blood test that can measure early biological changes linked to dementia risk. When Sandrine started to present our research at conferences, we realised we had something useful beyond the lab. Repeat interest from other researchers and clinicians made us realise that ‘maybe we’re not just answering a scientific question; we might actually have something that could make a real difference' - so we decided to explore the commercial path.

What initial steps did you take to explore the innovation?

The first step was to speak with the IP & Licensing team at King’s. They helped us understand the commercial potential of our work and supported us through the process of securing a patent for the assay. This was a pivotal moment because it turned what had been purely academic research, into something with real-world application.

Their guidance gave us the confidence to start thinking about our work differently – not just as a discovery, but as a product that could eventually reach patients and clinicians. Having this support early on made a big difference; it showed us that King’s not only valued our science but was also willing to back its potential beyond the lab.

Why did you decide to join King’s Spinout Accelerator?

We knew we had a strong scientific foundation but turning that into something people can actually use is a completely different challenge. The King’s Spinout Accelerator presented an opportunity to bridge that gap. It offered what we needed: practical guidance on how to build a venture, exposure to people who have done it before, and a structured environment where we could learn what it really takes to move from lab to market.

Edina’s energy, enthusiasm and experience in both academia and industry were key to us moving forward. Her belief that this wasn’t just a scientific idea and her drive to make it happen, played a big part in pushing us to apply.

More than anything, we wanted to build our confidence. As academics, it’s easy to feel like you’re not ‘business-minded’ enough, but this programme helped us see that you don’t need to have an MBA or a perfect plan. You just need to be open to learning, and willing to start.

A really important shift for us has been learning to step out of the lab mindset and think more like customers. We have started to do proper market research – talking to pharmaceutical companies, clinicians and potential end users to understand what they’re really looking for.– Prof. Sandrine Thuret & Dr Edina Silajdzic

You’re six months into your accelerator journey. What are your key learnings?

One of the biggest things we’ve learned is to stop waiting for things to be perfect before moving forward. In research, there’s a tendency to keep tweaking and improving before sharing anything, but that can really slow you down when you’re trying to build something new. The Accelerator has helped us shift that mindset. We’ve learned that progress often comes from putting something out there, testing it, and improving as you go.

It's also challenged a lot of internal doubts (e.g ‘I don’t know anything about business’ or ‘I’m not the kind of person who launches a company’). The Accelerator has shown us that we don’t need all the answers from the start. What matters is acting, asking for help, and staying open to learn.

Being part of a cohort of academics and researchers going through the same journey has been incredibly supportive. Everyone’s facing similar challenges, and there’s a real generosity in how people share what they’re learning. That sense of community has made a big difference and is motivating.

We’re learning that the version of the test we’ve built for research, might not be the same version that’s useful in the real world. That’s been a big eye-opener! We’re now in the process of adapting and shaping it based on what people actually need.– Prof. Sandrine Thuret & Dr Edina Silajdzic

What do you hope to achieve by the end of the Accelerator?

Our goal is to take real, practical steps towards turning this into a viable product. That means securing early funding, registering NeuroPrognostix as a company, and launching a minimum viable version of the test we can start piloting with partners.

We want to leave the programme not just with ideas, but with something tangible, something we can put in front of people, test, learn from, and continue developing. The Accelerator has already helped us move from thinking to doing, and our aim is to keep that momentum going.

***

The King's Spinout Accelerator offers a unique pathway to fast-track groundbreaking solutions born from research from across King's College London. It is open to all King's researchers and academics.

Learn more about NeuroPrognostix on their website.

 

In this story

Sandrine Thuret

Sandrine Thuret

Professor of Neuroscience

Latest news